On Wednesday, Shares of HP Inc (NYSE:HPQ), subtract -0.58% and closed at $15.35 in the last trading session. The last trading range of the stock ranges between $15.31 and $15.56. The company’s Market capitalization is $26.01 Billion with the total Outstanding Shares of 1.71 billion. During the 52-week trading session the minimum price at which share price traded, registered at $8.91 and reached to max level of $15.88. News Highlights:
Bolsters premium PC portfolio with focus on design, quality and performance.
Thin and light laptops with longer battery life exude quality materials and features.
Stunning all-in-one and display deliver cinematic experiences in the home.
HP Inc. recently unveiled its most recent generation premium consumer PC line-up for the 2016 holidays. The next generation portfolio features a thinner and lighter convertible with better battery life for portability and a beautifully designed all-in-one to bring amazing sound experiences into the home.
The premium portfolio is built to address customers’ need for devices that inspire and excite. Whether for within the home or on the go, the HP Premium products have become the gold standard for what customers expect from their computing experience. New products debuting recently include:
HP Spectre x360, the second generation of HP’s revolutionary x360 convertible now features a near zero border display in a design that is 13 percent thinner and 11 percent lighter.
HP ENVY laptop offers a sophisticated design offering up to 14 hours of battery life1, four more than the previous model.
HP ENVY AIO 27 combines computing power with media experiences that features a near borderless Technicolor Color Certified HD display that floats over an integrated four speaker sound bar tuned by Bang & Olufsen.
HP ENVY 27 Display a feature-rich 4K IPS display2 with a micro-edge bezel design for dual display set-ups.
Endo International plc – Ordinary Shares (NASDAQ:ENDP), dropped -4.06% and closed at $19.63 in the last trading session. The last trading range of the stock ranges between $19.50 and $20.77. The company’s Market capitalization is $4.56 Billion with the total Outstanding Shares of 222.77 million. Endo Pharmaceuticals Inc., a partner of Endo International plc (ENDP) (ENL.TO), recently declared new data to be presented evaluating the safety and efficacy of XIAFLEX®(collagenase clostridium histolyticum) (or CCH) injection under investigation for the treatment of palmar Dupuytren’s disease nodules. The findings will be presented during a podium presentation on Saturday, October 1, 2016 at 10:40 a.m. CDT at the annual meeting of the American Society for Surgery of the Hand (ASSH) held from September 29 to October 1, 2016 in Austin, Texas.
In a Phase 2, randomized, double-blind, placebo-controlled, dose-ranging study, in 75 adult study participants with Dupuytren’s disease and at least 1 nodule who received a single injection of CCH 0.40 mg or 0.60 mg, a statistically noteworthydecrease was shown from baseline in the mean nodule surface area (P≤0.001), consistency score (P<0.001) and hardness score (P≤0.01) at week 8 as compared to study participants receiving placebo. The safety profile of those treated with CCH was generally well tolerated. Adverse events included extremity pain, axillary pain, injection site-related adverse events and pruritus. One adverse event was stated as severe (injection site pain with CCH 0.60 mg). No patients were suspended from the study because of an adverse event.